TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00518986

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01442675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
Description: 0.5 mL, Intramuscular
Study: NCT05447637

Intervention type: DIAGNOSTIC_TEST
Intervention: Invitae multi-cancer gene panel
Description: Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.

Intervention type: DIAGNOSTIC_TEST
Intervention: Invitae multi-cancer gene panel
Description: Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
Study: NCT03640845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tele-expertise
Description: Tele-expertise consists of the remote realization of a multi-professional medication review (clinical pharmacist and doctor / geriatrician), ie a complete and systematic analysis of sociodemographic, clinical, biological and pharmaceutical data transmitted in such a way standardized at the EHMP and aimed at optimizing the therapeutics of the resident patient of the EHPAD requesting tele-expertise.~Tele-expertise is realized in three stages, that are~* the transmission, the collection and the organization of the data,~* the analysis of the data and their confrontation with the referential and recommendations~* the writing of a Personalized Pharmaceutical Plan
Study: NCT02324894

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI screening
Description: Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
Study: NCT00680381

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MTI, Minimal Transitional Intervention
Description: Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GTI, Group Transitional Intervention
Description: Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STI, Systems Transitions Intervention
Description: Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
Study: NCT03750799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Whole body vibration was applied on the right lower extremity in the experimental group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vibration
Description: Sham vibration was applied on the right lower extremity in the Control sham group
Study: NCT03718013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: accelerated deep TMS
Description: subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard deep TMS
Description: standard deep TMS treatment: once a day, during 4 weeks
Study: NCT00811005

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen or 5- methoxypsoralen
Description: Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 8-methoxypsoralen or 5methoxypsoralen
Description: PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen or 5methoxypsoralen
Description: PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet.
Study: NCT05022108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha bisabolol gel
Description: Using alpha bisabolol gel with a concentration of 0.5%, 2,5% or 5% to treat sensitized area with histamine.
Study: NCT04403971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine Oral Liquid Product
Description: The intervention group 1 received 10ml 0.12% chlorhexidine solution for oral rinse twice a day.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Listerine Oral Liquid Product
Description: The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Product
Description: The control group received 10ml normal saline for oral rinse twice a day.
Study: NCT02359448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
Study: NCT01321164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Body UV Therapy System UV 7002 plus fumaric acid esters
Description: Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.~Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months
Study: NCT01214811

Intervention type: DEVICE
Group type: OTHER
Intervention: Mepilex Border Ag
Description: Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
Study: NCT04921371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate® Cavity Protection Toothpaste
Description: Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: OTHER
Intervention: Colgate® Cavity Protection Toothpaste
Description: Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate® Cavity Protection Toothpaste
Description: Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate® Cavity Protection Toothpaste
Description: Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate® Cavity Protection Toothpaste
Description: Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine® Cool Mint®
Description: Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.

Intervention type: OTHER
Group type: OTHER
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concept Curve Winter Series Toothbrush
Description: Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% Hydroalcohol Mouthrinse
Description: Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthrinse Prototype 1
Description: Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthrinse Prototype 2
Description: Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
Study: NCT04159844

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: URGOBD001
Description: Application with 50% overlapping

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: URGOBD001
Description: Application with 50% overlapping

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: URGOBD001 associated with wading
Description: Application with 50% overlapping in association with wading
Study: NCT01321164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fumaric acid esters
Description: Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
Study: NCT00995592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Philani nutrition intervention program (mentor mothers)
Description: Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
Study: NCT04502381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled amp B deoxycholate+intravenous liposomal amp B
Description: Intravenous liposomal amphotericin B (beginning with 3mg/kg) along with inhaled amphotericin as below: Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited), will be dissolved in 10 mL distilled water. 2 mL of the reconstituted amphotericin B solution will be transferred into the drug chamber of a breath actuated nebulizer (Lupineb Ultra kit breath actuated nebulize which contains aeroclipse XL Reusable Breath Actuated Nebulizer and DeVilbiss 3655 compressor). 3 mL of distilled water is added to 2 mL of the reconstituted amphotericin B. The nebulization is continued till the chamber is emptied of the drug or the patient does not tolerate the therapy.~The first three doses of amphotericin B nebulization will be under the direct supervision of a physician. If tolerated, nebulization will be continued twice a day till tolerated or till response.The patient will complete a VAS score for cough after nebulization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous liposomal amphotericin B alone
Description: Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous liposomal amphotericin B alone
Description: Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated
Study: NCT01969916

Intervention type: DRUG
Group type: OTHER
Intervention: Regadenoson
Description: Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
Study: NCT01617369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: 2.8% NaCl x 4ml via nebulizer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline
Description: 2.8% NaCl x 4ml via nebulizer
Study: NCT02666651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
Study: NCT02769338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement Program
Description: The Intervention is a QI Program that will include multiple components as described above.
Study: NCT02966145

Intervention type: OTHER
Intervention: Observational Study

Intervention type: OTHER
Intervention: Observational Study

Intervention type: OTHER
Intervention: Observational Study
Study: NCT02924207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PATH electronic decision support tool
Description: PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
Study: NCT00580034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath Purged Non-myeloablative ASCT
Description: Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Donor Apheresis
Description: Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
Study: NCT02229305

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Treatment
Description: Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children
Description: Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita \& Weisz, 2010).
Study: NCT02973204

Intervention type: DRUG
Intervention: Sorafenib

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation (RFA) or surgery
Description: Intended curative surgery or RFA

Intervention type: DRUG
Intervention: Everolimus
Study: NCT03039296

Intervention type: PROCEDURE
Intervention: Endoscopic rhizotomy
Description: Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.

Intervention type: PROCEDURE
Intervention: Endoscopic rhizotomy
Description: Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.
Study: NCT01463176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
Study: NCT01006772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solid Ankle Foot Orthosis
Description: Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
Study: NCT05106842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Description: Aquatic therapy was performed in a swimming pool (depth 125-140 cm, temperature 28-31°C) supervised by a physiotherapist. Patients were asked to kneel or sit to submerge both shoulders to perform exercises consisting of progressive passive and active motion of the shoulder for 4-6 weeks, then strengthening exercises in a swimming pool for 2-4 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land-based Therapy
Description: Land-based therapy was performed at a rehabilitation center supervised by a physiotherapist. Patients performed progressive passive and active-assisted motion of the shoulder for 4-6 weeks, then strengthening exercises for 2-4 months.
Study: NCT04762914

Intervention type: OTHER
Intervention: Prehabilitation
Description: Prehabilitation is a multimodal and multidisciplinary person-centred perioperative approach involving supervised exercise training, nutritional education, management of polypharmacy and psychological advice.
Study: NCT04157894

Intervention type: OTHER
Intervention: Standard long-lasting insecticidal net
Description: Interceptor® (BASF) contains a pyrethroid insecticide

Intervention type: OTHER
Intervention: Chlorfenapyr insecticide treated net
Description: Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.

Intervention type: OTHER
Intervention: Piperonyl butoxide long-lasting insecticidal net
Description: PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
Study: NCT02524769

Intervention type: DRUG
Group type: OTHER
Intervention: conjugated estrogen
Description: 0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
Study: NCT02663219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
Study: NCT00945321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant 165 mg
Description: Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: aprepitant 185 mg
Description: Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: fosaprepitant 150 mg
Description: Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: aprepitant with food
Description: Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
Study: NCT03592797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser acupuncture therapy
Description: Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture therapy
Description: Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
Study: NCT03117426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYMFONY IOL
Description: IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AT LISA tri 839MP IOL
Description: IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
Study: NCT02246946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure
Description: To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
Study: NCT02973204

Intervention type: DRUG
Intervention: Lanreotide
Description: Or other somatostatin analogues (SSTA), eg. Sandostatin